Neurology International, Journal Year: 2024, Volume and Issue: 16(6), P. 1717 - 1730
Published: Dec. 5, 2024
Diabetes mellitus (DM) is a chronic disease associated with numerous complications, including cardiovascular diseases, nephropathy, and neuropathy. Sodium–glucose cotransporter 2 (SGLT-2) inhibitors, class of novel antidiabetic agents, have demonstrated promising therapeutic effects beyond glycemic control, potential benefits extending to the renal systems. Recently, research has increasingly focused on exploring role SGLT-2 inhibitors in preventing dementia. The aim this review summarize current suggesting that such as empagliflozin dapagliflozin, may neuroprotective reduce dementia risk improve cognitive function type diabetes patients. These are likely due better reduced oxidative stress, less advanced glycation end-product (AGE) formation, all linked neurodegeneration. Despite these findings, existing studies limited by small sample sizes short follow-up durations, which not adequately capture long-term outcomes. To establish more robust evidence, larger-scale, randomized controlled trials (RCTs) involving diverse populations needed. should involve focus understanding mechanisms behind effects. Addressing limitations will provide clearer guidelines for using prevention management. This help strategies health diabetic
Language: Английский